A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of FARAPULSE™ Pulsed Field Ablation Technology for Atrial Fibrillation
Objective
The purpose of this registry is to find out more about the outcomes for patients who receive an ablation using the Farapulse™ Pulsed Field Ablation System for the treatment for Paroxysmal Atrial Fibrillation (PAF), Persistent (PsAF) Atrial Fibrillation, and Long-Standing Persistent Atrial Fibrillation (LSPsAF).
Eligibility
Key Inclusion Criteria:
- Patients who, in the opinion of the Investigator, are candidates for ablation for AF
- Plans to undergo an ablation procedure using the FARAPULSE Pulsed Field Ablation System manufactured by Boston Scientific (as of July 1, 2026, patients enrolled must have procedures completed using the OPAL HDx mapping system, unless the subject is participating in a sub-study not requiring OPAL usage)
- 18 years of age or older
- Able and willing to participate in baseline and follow up evaluations for the full length of the registry
Key Exclusion Criteria:
- Enrolled in an investigational drug or device trial, or any trial that dictates the treatment plan without prior approval from Sponsor
- Currently receiving inotropic or mechanical support for Stage IV congestive heart failure, cardiogenic and/or septic shock.
- In the opinion of the Investigator, any known contraindication to an ablation procedure or to any device or drug required for use during an ablation procedure as assessed by the Investigator
NCT ID
NCT06335082
